Abstracts tagged "Prognostic factors and rheumatoid arthritis (RA)"

Abstract Number: 71 • 2018 ACR/ARHP Annual Meeting
Association of Shared Epitope and Poor Prognostic Factors in RA
Evo Alemao¹, Joshua Bryson¹, Christine K Iannaccone², Michelle Frits², Nancy A. Shadick³ and Michael Weinblatt², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a strong genetic association between RA and human leukocyte antigen (HLA) regions, particularly HLA-DRB1 alleles with the shared epitope (SE). SE alleles…
Abstract Number: 1456 • 2018 ACR/ARHP Annual Meeting
Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis
Mary Bach^1,2, Tiffany Pan³, J. Lee Nelson^3,4 and Christian Lood⁵, ¹VA Puget Sound Health Care System, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴Division of Rheumatology, University of Washington, SEATTLE, WA, ⁵Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation is associated with inflammation and autoimmunity, including rheumatoid arthritis (RA), where neutrophil infiltration into joints participates in tissue destruction and development of…
Abstract Number: 1480 • 2018 ACR/ARHP Annual Meeting
Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database
Eishi Uechi^1,2 and Kiyohide Fushimi², ¹Division of Rheumatology, Tomishiro Central Hospital, Okinawa, Japan, ²Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: Pneumonia is the leading cause of mortality in RA patients. No research has been conducted on the prognosis of pneumonia in RA patients. This…
Abstract Number: 1361 • 2017 ACR/ARHP Annual Meeting
How Often Do Rheumatologists Use Valid Prognostic Factors of Rheumatoid Arthritis? the Progresar Project
Teresa Oton-Sanchez¹, Loreto Carmona², Sara Luján³, Ana Royo³, Jose Luis Baquero⁴ and Santiago Muñoz-Fernandez⁵, ¹InMusc. Instituto de Salud Músculo-Esquelética, Madrid, Spain, ²Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ³Medical Department Bristol-Myers Squibb, Madrid, Spain, ⁴Scientific Department Scientia Salus, Madrid, Spain, ⁵Rheumatology, Hospital Universitario Infanta Sofia. Universidad Europea, Madrid, Spain
Background/Purpose: Prognostic factors facilitate decisions on treatment and follow-up of patients with rheumatoid arthritis (RA). Rheumatologists might use factors with poor link to evidence in…
Abstract Number: 1375 • 2017 ACR/ARHP Annual Meeting
Foot Arthritis : Poor Prognosis Factor in RA
Sung-Hae Chang¹, Sung Won Lee², Mi-Il Kang³ and Seong Yong Kim⁴, ¹Soonchunhyang University Cheonan Hospital, Cheonan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, Soonchunhyang University Cheonan Hospital, Cheonan, Korea, Republic of (South), ³Dankuk University Hospital, Cheonan, Korea, Republic of (South), ⁴Application Statistics, Hoseo University, Cheonan, Korea, Republic of (South)
Background/Purpose: The objective of the current study is to evaluate the clinical importance of foot and ankle joint arthritis.Methods: Data from Korean Biologic Registry (KoBio)…
Abstract Number: 1455 • 2017 ACR/ARHP Annual Meeting
Investigation of Poor Prognostic Factors Among Rheumatoid Arthritis Patients in Turkbio Registry
Nevsun Inanc¹, Zeynep Erturk¹, Gulsen Ozen¹, Ediz Dalkilic², Suleyman Serdar Koca³, Gerçek Can⁴, Ahmet Karatas⁵, Yavuz Pehlivan⁶, Ayten Yazici⁷, Ayse Cefle⁷, Servet Akar⁸, Soner Senel⁹, Burak Oz³, Nurullah Akkoc¹⁰, Haner Direskeneli¹ and Fatos Onen¹¹, ¹Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ³Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁴Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ⁵Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, ⁶Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, ⁷Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, ⁸Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁹Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, ¹⁰Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, ¹¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: TURKBIO is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011.In 2016,the EULAR RA management guideline recommended assessment of…
Abstract Number: 1468 • 2017 ACR/ARHP Annual Meeting
Abatacept Retention Rates, Overall and By Participating Country, and Prognostic Factors of Retention in Patients with RA: 2-Year Results from a Real-World Observational Study
Rieke Alten¹, HM Lorenz², X Mariette³, HG Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen, Nürnberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION (NCT02109666) was the first prospective international non-interventional study designed to provide long-term real-world data on abatacept retention in patients (pts) with RA. The…
Abstract Number: 2386 • 2017 ACR/ARHP Annual Meeting
The Risk Factors of Newly Developing/Worsening Pulmonary Abnormalities in Rheumatoid Arthritis
Ayae Tanaka¹, Kazuhiro Kurasawa¹, Yuta Takamura¹, Tomoyuki Miyao¹, Ryutaro Yamazaki², Satoko Arai¹, Takayoshi Owada¹, Reika Maezawa¹ and Masafumi Arima¹, ¹Rheumatology, Dokkyo Medical University, Mibu, Tochigi, Japan, ²Rheumatology, Dokkyo Medical University, Mibu, tochigi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects various organs including the lung. The pulmonary involvement is critical for prognosis of the…
Abstract Number: 2405 • 2017 ACR/ARHP Annual Meeting
Biological Function Integrated Prediction of Severe Radiographic Progression in Rheumatoid Arthritis: A Nested Case Control Study
Young Bin Joo¹, Yul Kim², Youngho Park³, Kwangwoo Kim⁴, Jeong Ah Ryu⁵, Seunghun Lee⁶, So-Young Bang⁷, Hye-Soon Lee⁸, Gwan-Su Yi⁹ and Sang-Cheol Bae⁷, ¹Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South), ²Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea, Republic of (South), ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴4Department of Biology, Kyung Hee University, Seoul, Korea, Republic of (South), ⁵Department of Radiology, Hanyang University Hospital, Seoul, Korea, Republic of (South), ⁶17 Haengdang-Dong, Seongdong-G, Hanyang University Hospital, Seoul, Korea, Republic of (South), ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁸Hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of (South), ⁹Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea, Republic of (South)
Background/Purpose: Radiographic progression is reported to be highly heritable in rheumatoid arthritis (RA). However, previous study using genetic loci showed an insufficient accuracy of prediction…
Abstract Number: 2421 • 2017 ACR/ARHP Annual Meeting
Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis
Tomohiro Koga¹, Tomohito Sato¹, Masataka Umeda², Shoichi Fukui², Ayako Nishino¹, Shinya Kawashiri², Naoki Iwamoto², Kunihiro Ichinose², Mami Tamai¹, Tomoki Origuchi³, Hideki Nakamura² and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease arising from a breakdown of peripheral tolerance, which leads to aberrant Th1- or Th17-driven immune…
Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting
In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
Rieke Alten¹, HM Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, J Heitzmann⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
Abstract Number: 552 • 2016 ACR/ARHP Annual Meeting
Disability in Early Rheumatoid Arthritis, Course and Predictors
Therese Hansson^1,2, Christina Book^1,2, Lennart T.H. Jacobsson^1,3 and Carl Turesson^1,2, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
Background/Purpose: Patient reported outcome measures (PROMs), including the Health Assessment Questionnaire Disability Index (HAQ-DI), are valuable and reliable instruments for assessment of disease severity and…
Abstract Number: 3151 • 2016 ACR/ARHP Annual Meeting
The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Paul Studenic¹, Stephan Blüml², Holger Bang³, Manuel Unger⁴, Karim Raza⁵, Daniel Aletaha⁶, Josef S. Smolen^7,8 and Günter Steiner⁹, ¹Department of Internal Medicine 3, Division of Rheumatology and Geriatric Medicine, Medical University Vienna, Vienna, Austria, ²Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rsearch & Development, Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, United Kingdom, Birmingham, United Kingdom, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁷2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁸Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have recently been described in rheumatoid arthritis (RA) patients and may be used as a further diagnostic marker in patients with…
Abstract Number: 504 • 2016 ACR/ARHP Annual Meeting
Clinical Significance of Multiple Autoantibody Specificities in Rheumatoid Arthritis: The Role of Anti-Citrullinated Alpha-Enolase and Anti-Interferon Inducible Protein 16 Antibodies
Alessia Alunno¹, Onelia Bistoni¹, Federico Pratesi², Valeria Caneparo³, Fabiana Topini¹, Ilaria Puxeddu², Marco De Andrea⁴, Santo Landolfo⁴, Paola Migliorini² and Roberto Gerli¹, ¹Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ²Department of Clinical and Experimental Medicine, Clinical Immunology Unit, University of Pisa, Pisa, Italy, ³Department of Translational Medicine, Virology Unit, Novara Medical School, Novara, Italy, ⁴Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, Turin Medical School, Torino, Italy
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) auto-antibodies (auto-Abs) represent the current gold standard for the diagnosis of rheumatoid arthritis (RA). However, growing evidence suggests that a…
Abstract Number: 532 • 2015 ACR/ARHP Annual Meeting
Plasma Levels of Bone Morphogenetic Protein (BMP) Subgroups and Their Inhibitors (noggin, sclerostin) in Rheumatoid Arthritis Patients and Correlation with Disease Activity, Clinical and Radiographic Progression: Preliminary Results
Ozge Kockara¹, Sebnem Ataman², Merve Sibel Gungoren³, Filiz Akbiyik³ and Erdem Karabulut⁴, ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, ³Medical Biochemistry, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Biostatistics, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory disease that leads to bone erosion. Bone morphogenetic proteins (BMPs) have favourable effects in the recovery of bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].